Eric Dube, Travere Therapeutics CEO
May 26, 2021 09:39 AM EDT
FDA+

Tra­vere takes a hit as FDA staffers shoo off their ac­cel­er­at­ed drug pitch

John Carroll

Editor & Founder

Three months af­ter the ex­ecs at Tra­vere Ther­a­peu­tics $TVTX picked up in­ter­im da­ta for its treat­ment for a rare kid­ney dis­ease and made a bee­line …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

TRENDING NOW

Big leas­es, big­ger re­grets: Biotech slump turns swanky of­fices from as­set in­to li­a­bil­i­ty

Al­tos Labs buys an­ti-ag­ing start­up Do­ri­an Ther­a­peu­tics

Genen­tech ex­pands deal with mol­e­c­u­lar glue biotech Ori­o­n­is for $105M up­front

How PureTech’s lung fi­bro­sis drug stacks up against the com­pe­ti­tion

Co­caine vac­cine, a long­shot at­tempt to quell crav­ings, yields mixed da­ta in small study

sponsored

Does your sup­ply chain hold up un­der pres­sure for high-risk tem­per­a­ture-crit­i­cal ship­ments?

A service from the Financial Times